EUVIMEDEUVIMED entdecken
Crossref

The novel peptide DBCH reduces LPS-stimulated NF-κB/MAPK signaling in BV-2 microglia and ameliorates cognitive impairment in scopolamine-treated mice by modulating BDNF/CREB

Ye-Ji Yu, Mujeeb Ur Rahman, Rengasamy Balakrishnan, Jong-Min Kim, Jae Ho Kim, Dong-Kug Choi

Neurochemistry International · 2025

DOI: 10.1016/j.neuint.2025.105946 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurochemistry International, 2025. Verfasst von Ye-Ji Yu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Life Sciences, Graduate School, BK21 Program, Konkuk University, Chungju, 27478, South Korea. Hauptthemen laut MEDLINE: Microglia, Scopolamine, Cognitive Dysfunction, Brain-Derived Neurotrophic Factor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Ministry of SMEs and Startups, National Research Foundation of Korea, Korea Technology and Information Promotion Agency for SMEs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Microglial-mediated neuroinflammation significantly impacts cognitive impairment, and modulating neuroinflammatory responses has emerged as a promising target for treatment. However, the specific role of microglial-mediated neuroinflammation in cognitive impairment associated with Alzheimer's disease (AD) remains unclear. In our continuous endeavors to seek potent anti-Alzheimer's agents, we recently synthesized and developed a series of peptidomimetic compounds, including dipeptide-68 bis-cyclohexylpropyl histidinamide (DBCH), derived from a caryopsis-1 peptide that has demonstrated anti-inflammatory and anti-microbial properties in various infectious diseases. Among the bioactive peptides synthesized, DBCH exhibited good neuroprotective and anti-inflammatory activity and high potency. Therefore, in this study, the neuroprotective and anti-inflammatory effects of DBCH were assessed in lipopolysaccharide (LPS)-stimulated BV-2 microglial cells and a scopolamine-induced C57BL/6 N amnesic mouse model. In the in vitro study, DBCH effectively suppressed the production and expression of nitric oxide (NO) and proinflammatory cytokines in BV-2 microglial cells stimulated with LPS. Furthermore, it effectively inhibited the LPS-triggered phosphorylation and activation of NF-κB/MAPK signaling and modulated inflammatory mediators, including iNOS and COX-2, in BV-2 microglial cells. In vivo results showed that DBCH administration of 5 or 10 mg/kg improved spatial memory learning and cognitive function in scopolamine-induced amnesic mice. Furthermore, DBCH treatment upregulated phosphorylated cAMP-response element-binding protein (p-CREB) and brain-derived neurotrophic factor (BDNF) levels and downregulated the inflammatory response. Overall, DBCH effectively prevented both scopolamine-induced cognitive impairment and neuroinflammation. Our research findings suggest that DBCH may serve as a medication for cognitive decline associated with AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicrogliaScopolamineCognitive DysfunctionBrain-Derived Neurotrophic FactorNF-kappa BCyclic AMP Response Element-Binding ProteinMAP Kinase Signaling SystemPeptidesAnimalsLipopolysaccharidesMiceMice, Inbred C57BLMaleNeuroprotective AgentsSignal Transduction

Stichwörter der Autor:innen

Alzheimer's diseaseCognitive impairmentDBCHNeuroinflammationNeuroprotectionScopolamine

Substanzen

ScopolamineLipopolysaccharidesBrain-Derived Neurotrophic FactorNF-kappa BCyclic AMP Response Element-Binding ProteinBdnf protein, mouseNeuroprotective AgentsPeptidesCreb1 protein, mouse

Autor:innen und Institutionen

  • Department of Applied Life Sciences, Graduate School, BK21 Program, Konkuk University, Chungju, 27478, South Korea.
  • Department of Biotechnology, College of Biomedical and Health Science, Research Institute of Inflammatory Disease (RID), Konkuk University, Chungju, 27478, South Korea.
  • Division of R&D, WellPep Co., LTD, 172, Dolma-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea.
  • Department of Applied Life Sciences, Graduate School, BK21 Program, Konkuk University, Chungju, 27478, South Korea; Department of Biotechnology, College of Biomedical and Health Science, Research Institute of Inflammato…

Förderung

  • Ministry of SMEs and Startups
  • National Research Foundation of Korea
  • Korea Technology and Information Promotion Agency for SMEs

Zitieren

APA

Yu, Y. J., Rahman, M. U., Balakrishnan, R., Kim, J. M., Kim, J. H., & Choi, D. K. (2025). The novel peptide DBCH reduces LPS-stimulated NF-κB/MAPK signaling in BV-2 microglia and ameliorates cognitive impairment in scopolamine-treated mice by modulating BDNF/CREB. Neurochemistry International. https://doi.org/10.1016/j.neuint.2025.105946

Vancouver

Yu YJ, Rahman MU, Balakrishnan R, Kim JM, Kim JH, Choi DK. The novel peptide DBCH reduces LPS-stimulated NF-κB/MAPK signaling in BV-2 microglia and ameliorates cognitive impairment in scopolamine-treated mice by modulating BDNF/CREB. Neurochemistry International. 2025. doi:10.1016/j.neuint.2025.105946

BibTeX
@article{Yu2025,
  author = {Yu, Ye-Ji and Rahman, Mujeeb Ur and Balakrishnan, Rengasamy and Kim, Jong-Min and Kim, Jae Ho and Choi, Dong-Kug},
  title = {The novel peptide DBCH reduces LPS-stimulated NF-κB/MAPK signaling in BV-2 microglia and ameliorates cognitive impairment in scopolamine-treated mice by modulating BDNF/CREB},
  journal = {Neurochemistry International},
  year = {2025},
  doi = {10.1016/j.neuint.2025.105946}
}
Kostenlos starten →